We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- New clinical guidelines
- Managing cardiovascular risk factors
- How do we define response at 1 year?
- Benefits of 10 kg weight loss
- Why to treat pharmacologically? (1)
- Weight loss and cardiovascular risk
- Why to treat pharmacologically? (2)
- What is success in weight management?
- Why to treat pharmacologically? (3)
- The STORM study on body weight changes
- Characteristics ideal anti-obesity agent (1 )
- Topiromate has a dose-dependent effect
- Characteristics ideal anti-obesity agent (2)
- Drug therapy - for whom to consider?
- Previous drugs used in obesity treatment
- Previous experience with anti-obesity drugs
- Recent experience with anti-obesity drugs
- Sibutramine has dual physiological action
- Sibutramine has a dual transmitter effect
- Pharmacology of centrally acting agents
- Normal neural function
- Different mode of action for centrally acting drugs
- Weight loss at endpoint
- Patients obtaining a weight loss >10% in 1 year
- STORM study: 8 European centres
- STORM study: body weight changes over 2 years
- Intensified behavioural and dietary intervention
- Leisure activity contributes to weight maintenance
- Recent experience with anti-obesity drugs: Orlistat
- Physiology of fat absorption
- Orlistat inhibits lipase activity
- Lipase inhibition: mechanism of action
- Orlistat can inhibit absorption of 30% of dietary fat
- 1-year weight loss with orlistat
- % of patients who achieved meaningful weight loss
- Sub-analysis of orlistat studies
- Post-absorptive nutrient partitioning
- Involvement of cannabinoid system
- Cannabinoid (CB) receptors
- Sites of CB1 receptors and effects of its blockade
- Rimonabant - the first CB1 blocker
- Changes in weight and waist
- Change in HDL-cholestrol and triglycerides
- Changes in leptin and adiponectin
- Body weight changes with CB1-blockade
- Future experience to be made
- Drugs altering energy intake
- Time course of body weight with exenatides
- Drugs and their extra "beyond" benefits (1)
- Effect of orlistat on LDL-cholesterol
- Change in LDL-cholesterol after 1 year
- The STORM study and lipid changes
- Effects of sibutramine on HDL
- Improvements in lipid parameters with rimonabant
- Improvement in fasting insulin/insulin resistance
- Pharmacotherapy and diabetes
- Overweight type II diabetic vs. non-diabetic
- Weight loss in diabetic and non diabetic patients
- Initial weight loss of >5% / 10% in orlistat patients
- Weight/waist perimeter changes (diabetic patients)
- Drugs and their extra "beyond" benefits (2)
- XENDOS study objectives
- Changes in body weight in XENDOS trial
- Cumulative incidence of type II diabetes
- Orlistat - side effects
- Sibutramine - side effects
- Rimonabant - side effects
- Time for action
Topics Covered
- Pharmacotherapy as target for 5 to 10 % weight loss option
- Pharmacotherapy as an additional approach for weight management programs
- Characteristics of appropriate anti-obesity agents
- Actual experience with anti-obesity agents
- Potential new agents for the future
- Metabolic "beyond weight loss" effects
- Safety
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Van Gaal, L. (2007, October 1). New standards in weight management: recent and future drugs for the treatment of obesity [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2024, from https://doi.org/10.69645/BZUB6713.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Luc Van Gaal has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
New standards in weight management: recent and future drugs for the treatment of obesity
A selection of talks on Metabolism & Nutrition
Hide